Literature DB >> 11459432

Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide.

A W Wright1, L E Mather, M T Smith.   

Abstract

In humans, hydromorphone (HMOR) is metabolised principally by conjugation with glucuronic acid to form hydromorphone-3-glucuronide (H3G), a close structural analogue of morphine-3-glucuronide (M3G), the major metabolite of morphine. In a previous study we described the biochemical synthesis of H3G together with a preliminary evaluation of its pharmacology which revealed that it is a neuroexcitant in rats in a manner analogous to M3G. Thus the aims of the current study were to quantify the neuro-excitatory behaviours evoked by intracerebroventricular (icv) H3G in the rat and to define its potency relative to M3G. Groups of adult male Sprague-Dawley rats received icv injections (1 microL) of H3G (1 - 3 microg), M3G (2 - 7 microg) or vehicle via a stainless steel guide cannula that had been implanted stereotaxically seven days prior to drug administration. Behavioural excitation was monitored by scoring fifteen different behaviours (myoclonic jerks, chewing, wet-dog-shakes, rearing, tonic-clonic-convulsions, explosive motor behaviour, grooming, exploring, general activity, eating, staring, ataxia, righting reflex, body posture, touch evoked agitation) immediately prior to icv injection and at the following post-dosing times: 5, 15, 25, 35, 50, 65 and 80 min. H3G produced dose-dependent behavioural excitation in a manner analogous to that reported previously for M3G by our laboratory and reproduced herein. H3G was found to be approximately 2.5-fold more potent than M3G, such that the mean (+/- S.D.) ED50 values were 2.3 (+/- 0.1) microg and 6.1 (+/- 0.6) microg respectively. Thus, our data clearly imply that if H3G crosses the BBB with equivalent efficiency to M3G, then the myoclonus, allodynia and seizures observed in some patients dosed chronically with large systemic doses of HMOR, are almost certainly due to the accumulation of sufficient H3G in the central nervous system, to evoke behavioural excitation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11459432     DOI: 10.1016/s0024-3205(01)01133-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  17 in total

Review 1.  Advances in opioid pharmacology.

Authors:  Geoffrey K Gourlay
Journal:  Support Care Cancer       Date:  2004-12-21       Impact factor: 3.603

Review 2.  Contribution to variability in response to opioids.

Authors:  Geoffrey W Hanks; Colette Reid
Journal:  Support Care Cancer       Date:  2004-12-10       Impact factor: 3.603

Review 3.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 4.  OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

Review 5.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

6.  Hydromorphone-induced Neurostimulation in a Yorkshire Swine (Sus scrofa) after Myocardial Infarction Surgery.

Authors:  Inés Rodriguez; Blythe H Philips; Emily L Miedel; Lauren A Bright; Philip C LaTourette Ii; Anthony J Carty; Walter R Witschey; Robert C Gorman; Joseph H Gorman Iii; James O Marx
Journal:  J Am Assoc Lab Anim Sci       Date:  2019-08-26       Impact factor: 1.232

Review 7.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 8.  Demographics, assessment and management of pain in the elderly.

Authors:  Mellar P Davis; Manish Srivastava
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Adult cancer pain.

Authors:  Robert A Swarm; Amy Pickar Abernethy; Doralina L Anghelescu; Costantino Benedetti; Sorin Buga; Charles Cleeland; Oscar A Deleon-Casasola; June G Eilers; Betty Ferrell; Mark Green; Nora A Janjan; Mihir M Kamdar; Michael H Levy; Maureen Lynch; Rachel M McDowell; Natalie Moryl; Suzanne A Nesbit; Judith A Paice; Michael W Rabow; Karen L Syrjala; Susan G Urba; Sharon M Weinstein; Mary Dwyer; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2013-08       Impact factor: 11.908

Review 10.  Pediatric palliative care: use of opioids for the management of pain.

Authors:  Boris Zernikow; Erik Michel; Finella Craig; Brian J Anderson
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.